Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM) announced that its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., will speak at the 2021 Wedbush PacGrow Healthcare Conference on Aug. 10, 2021, at 9:10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., will speak at the 2021 Wedbush PacGrow Healthcare Conference on Aug. 10, 2021, at 9:10 a.m. ET. The panel discussion, titled “So Let it Be (Re)Written - Updates in Gene Modulation,” will be available via a live webcast on the company's investor website and archived for 60 days. Beam Therapeutics specializes in precision genetic medicines through its proprietary base editing technology, allowing precise genomic alterations without DNA breaks.
Details
News Market Reaction – BEAM
The recorded move for BEAM in the trading session of this news was +1.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president and chief scientific officer of Beam, will participate in a panel titled, “So Let it Be (Re)Written - Updates in Gene Modulation” during the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 10, 2021 at 9:10 a.m. ET.
The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.